Inflammation-related IL1β/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma

Cancer Prevention Research

Volumn 9, Issue 5, 2016, Pages 406-414

  Kadariya, Yuwaraj ^a   Menges, Craig W ^a   Talarchek, Jacqueline ^a   Cai, Kathy Q ^a   Klein Szanto, Andres J ^a   Pietrofesa, Ralph A ^b   Christofidou Solomidou, Melpo ^b   Cheung, Mitchell ^a   Mossman, Brooke T ^c   Shukla, Arti ^c   Testa, Joseph R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASBESTOS; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA; APOPTOSIS REGULATORY PROTEIN; PYCARD PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CARCINOGENESIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME PHOSPHORYLATION; HISTOLOGY; IMMUNOBLOTTING; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; DEFICIENCY; DISEASE MODEL; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; LUNG TUMOR; MESOTHELIOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; ASBESTOS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTERLEUKIN-1BETA; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, KNOCKOUT; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84970044306     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0347     Document Type: Article

References (42)

1. Wagner JC, Slegga CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 1960;17:260-71.
2. Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health 2013;19:1-10.
3. Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Saves M, deQuillacq A, et al. The French National Mesothelioma Surveillance Program. Occup Environ Med 2006;63:390-5.
4. Burki T. Health experts concerned over India's asbestos industry. Lancet 2010;375:626-7.
5. Flejter WL, Li FP, Antman KH, Testa JR. Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes. Genes Chromosomes Cancer 1989;1:148-54.
6. Cheng JQ, Jhanwar SC, Klein WM, Bell DW, Lee W-C, Altomare DA, et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 1994;54:5547-51.
7. Xio S, Li D, Vijg J, Sugarbaker DJ, Corson JM, Fletcher JA. Codeletion of p15 and p16 in primary malignant mesothelioma. Oncogene 1995;11: 511-5.
8. Bianchi AB, Mitsunaga S-I, Cheng JQ, Klein WM, Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primarymalignantmesotheliomas. Proc Natl Acad Sci U S A 1995;92:10854-8.
9. Sekido Y, Pass HI, Bader S, Mew DJY, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31.
10. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43: 668-72.
11. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011; 43:1022-5.
12. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005;65:8090-5.
13. Altomare DA, Menges CW, Pei J, Zhang L, Skele-Stump KL, Carbone M, et al. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas fromArf knockout mice. Proc Natl Acad Sci U S A 2009;106:3430-5.
14. Altomare DA, Menges CW, Xu J, Pei J, Zhang L, Tadevosyan A, et al. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis. PLoS One 2011;6:e18828.
15. Xu J, Kadariya Y, Cheung M, Pei J, Talarchek J, Sementino E, et al. Germline mutation of Bap1 accelerates development of asbestos-induced malignant mesothelioma. Cancer Res 2014;74:4388-97.
16. Napolitano A, Pellegrini L, Dey A, Larson D, Tanji M, Flores EG, et al. Minimal asbestos exposure in germline BAP1 heterozygous mice is associated with deregulated inflammatory response and increased risk of mesothelioma. Oncogene 2015 Jun 29. [Epub ahead of print].
17. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009;11:615-28.
18. Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo AL, Jarnicki AG, Himbeck RP, Davis MR, et al. Patho-and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leucocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994;39:347-59.
19. Stadlmann S, Pollheimer J, Renner K, Zeimet AG, Offner FA, Amberger A. Response of human peritoneal mesothelial cells to inflammatory injury is regulated by interleukin-1beta and tumor necrosis factor-alpha. Wound Repair Regen 2006;14:187-94.
20. Wang Y, Faux SP, Hallden G, Kirn DH, Houghton CE, Lemoine NR, et al. Interleukin-1beta and tumour necrosis factor-alpha promote the transformation of human immortalised mesothelial cells by erionite. Int J Oncol 2004;25:173-8.
21. Miselis NR, Wu ZJ, Van Rooijen N, Kane AB. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008;7:788-99.
22. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006;98:723-34.
23. Mariathasan S, Newton K, Monack DM, Vucic D, French DM, Lee WP, et al. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature 2004;430:213-8.
24. Pedra JH, Cassel SL, Sutterwala FS. Sensing pathogens and danger signals by the inflammasome. Curr Opin Immunol 2009;21:10-6.
25. Willingham SB, Bergstralh DT, O'Connor W, Morrison AC, Taxman DJ, Duncan JA, et al.Microbial pathogen-induced necrotic cell death mediated by the inflammasome componentsCIAS1/cryopyrin/NLRP3 and ASC.Cell Host Microbe 2007;2:147-59.
26. Gasse P, Mary C, Guenon I, Noulin N, Charron S, Schnyder-Candrian S, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 2007;117: 3786-99.
27. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 2008;320:674-7.
28. Cassel SL, Eisenbarth SC, Iyer SS, Sadler JJ, Colegio OR, Tephly LA, et al. The Nalp3 inflammasome is essential for the development of silicosis. Proc Natl Acad Sci U S A 2008;105:9035-40.
29. Menges CW, Kadariya Y, Altomare D, Talarchek J, Neumann-Domer E, Wu Y, et al. Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR34a-c-Met axis. Cancer Res 2014;74:1261-71.
30. Serrano M, Lee H-W, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996; 85:27-37.
31. McClatchey AI, Saotome I, Mercer K, Crowley D, Gusella JF, Bronson RT, et al. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev 1998; 12:1121-33.
32. Marsella JM, Liu BL, Vaslet CA, Kane AB. Susceptibility of p53-deficient mice to induction of mesothelioma by crocidolite asbestos fibers. Environ Health Perspect 1997;105:1069-72.
33. Macdonald JL, Kane AB. Mesothelial cell proliferation and biopersistence of wollastonite and crocidolite asbestos fibers. Fund Appl Toxicol 1997;38:173-83.
34. Davis JM, Dungworth DL, Boorman GA. Concordance in diagnosis of mesotheliomas. Toxicol Path 1996;24:662-3.
35. Xiao G, Gallagher R, Shetler J, Skele K, Altomare D, Pestell R, et al. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005; 25:2384-94.
36. Menges CW, Chen Y, Mossman BT, Chernoff J, Yeung AT, Testa JR. A phosphotyrosine proteomic screen identifies multiple tyrosine kinase signaling pathways aberrantly activated in malignant mesothelioma. Genes Cancer 2010;1:493-505.
37. Chow MT, Tschopp J, Moller A, Smyth MJ. NLRP3 promotes inflammationinduced skin cancer but is dispensable for asbestos-induced mesothelioma. Immunol Cell Biol 2012;90:983-6.
38. Hillegass JM, Miller JM, MacPherson MB, Westbom CM, Sayan M, Thompson JK, et al. Asbestos and erionite prime and activate the NLRP3 inflammasome that stimulates autocrine cytokine release in human mesothelial cells. Part Fibre Toxicol 2013;10:39.
39. Benko S, Philpott DJ, Girardin SE. The microbial and danger signals that activate Nod-like receptors. Cytokine 2008;43:368-73.
40. Bethea JR, Chung IY, Sparacio SM, Gillespie GY, Benveniste EN. Interleukin-1 beta induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. J Neuroimmunol 1992;36:179-91.
41. Cahill CM, Rogers JT. Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J Biol Chem 2008;283:25900-12.
42. Moalli PA, MacDonald JL, Goodglick LA, Kane AB. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 1987;128:426-45.